球囊类产品

Search documents
近亿元融资!血管介入创新企业完成B+轮
思宇MedTech· 2025-04-30 11:54
正式报名:首届全球心血管大会 | 赠送纸质白皮书 合作伙伴征集:2025全球手术机器人大会 近日, 科塞尔医疗科技(苏州)有限公司 宣布完成近亿元 B+轮融资,此轮融资由铁投巨石领投,苏高新金 控持续追加投资,园雍投资跟投,所筹资金主要用于核心产品研发、全球市场推广及产能扩建。 历次融资情况 技术平台与专利 : 科塞尔医疗累计研发投入超 3 亿元, 构建了丰富技术平台,拥有近百人研发、工艺和 注册团队,取得国内外发明专利数百项,包括 PCT 专利近百项。 核心产品与应用领域 : 其外周领域的创新产品腔 静脉滤器 成功注册并顺利商业化,是国内首个获准注册 的伞形长效滤器。 冠脉领域的球囊类产品获得中国 NMPA、美国 FDA、欧盟 CE、日本 PMDA、韩国 KFDA 等多国注册证书并进入国际主流市场。目前已有两个创新产品成功商业化。 市场表现 :公司产品已在国内 2000 家医院使用,在海外 20 余个国家完成产品注册。 2017 年初 :完成由达晨财智中国风险投资基金领投的数千万元 Pre - A 轮融资。 2018 年中 :获得博远资本领投,达晨财智跟投的数千万元 A 轮融资。 2020 年底 :完成由渶 ...
铁投巨石领投,科塞尔医疗完成近亿元B+轮融资
Sou Hu Cai Jing· 2025-04-28 08:43
Core Insights - Koser Medical Technology (Suzhou) Co., Ltd. has completed nearly 100 million yuan in B+ round financing, led by Tietou Jushi, with funds allocated for core product development, global market promotion, and capacity expansion [1] Company Overview - Koser Medical was established in November 2013 and is a platform company with comprehensive production and R&D capabilities in vascular interventional devices, aiming to provide systematic solutions for clinical applications [1] - The company has successfully commercialized its innovative product, the inferior vena cava filter, which is the first umbrella-shaped long-term filter approved for registration in China, with several other innovative products set to enter clinical trials [1] - Koser Medical's balloon products in the coronary field have received registration certificates from multiple countries, including China (NMPA), the USA (FDA), the EU (CE), Japan (PMDA), and South Korea (KFDA), and have entered mainstream international markets [1] Leadership - The Chairman, General Manager, and CEO, Hu Qing, is a member of the second Life Science Instrument Professional Committee of the Chinese Society of Biomedical Engineering and has received multiple honors. He has extensive experience in management roles at Fortune 500 companies and has been in the medical device industry since 2002 [1] Financing History - The company has completed four rounds of financing prior to the recent B+ round, with investors including Dacheng Caizhi and Jushi Chuangtou [2] Business Structure - Koser Medical has formed a "one core, three wings" business layout, with the parent company focusing on a one-stop treatment system for peripheral intervention, while subsidiaries specialize in cardiac electrophysiology, coronary intervention product development, and breakthrough core medical materials technology [3] Global Strategy - The company actively practices a "Local Base, Global Reach" strategy, having acquired Ireland's Micell in 2021 to gain access to extensive clinical data and special coating technology, marking a significant step towards globalization [3] - Koser Medical has completed product registrations in over 20 countries and plans to establish more overseas subsidiaries and offices, with global sales set to officially launch in 2024 and aims for large-scale international expansion by 2026 [3]